CDKN2A and central nervous system cancer: Some studies have shown that co-deletion of CDKN2A and MTAP could be used as markers for glioma stratification, and the deletion of CDKN2A was associated with the expression of CDK4/6 in various tumors (Kaul et al., 2015; Frazao et al., 2018).